Recursion Pharmaceuticals Statistics
Total Valuation
RXRX has a market cap or net worth of $2.25 billion. The enterprise value is $2.00 billion.
| Market Cap | 2.25B |
| Enterprise Value | 2.00B |
Important Dates
The last earnings date was Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RXRX has 237.52 million shares outstanding. The number of shares has increased by 23.17% in one year.
| Shares Outstanding | 237.52M |
| Shares Change (YoY) | +23.17% |
| Shares Change (QoQ) | +6.25% |
| Owned by Insiders (%) | 5.15% |
| Owned by Institutions (%) | 97.13% |
| Float | 191.96M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 48.68 |
| Forward PS | 39.73 |
| PB Ratio | 5.61 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 43.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.65, with a Debt / Equity ratio of 0.13.
| Current Ratio | 4.65 |
| Quick Ratio | 4.09 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -80.00% and return on invested capital (ROIC) is -83.28%.
| Return on Equity (ROE) | -80.00% |
| Return on Assets (ROA) | -56.50% |
| Return on Capital (ROIC) | -83.28% |
| Revenue Per Employee | $92,470 |
| Profits Per Employee | -$708,224 |
| Employee Count | 500 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.84M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +75.09% in the last 52 weeks. The beta is 0.85, so RXRX's price volatility has been lower than the market average.
| Beta (1Y) | 0.85 |
| 52-Week Price Change | +75.09% |
| 50-Day Moving Average | 9.20 |
| 200-Day Moving Average | 8.98 |
| Relative Strength Index (RSI) | 56.02 |
| Average Volume (30 Days) | 6,234,654 |
Short Selling Information
The latest short interest is 40.50 million, so 17.05% of the outstanding shares have been sold short.
| Short Interest | 40.50M |
| Short Previous Month | 38.70M |
| Short % of Shares Out | 17.05% |
| Short % of Float | 21.10% |
| Short Ratio (days to cover) | 9.27 |
Income Statement
In the last 12 months, RXRX had revenue of $46.24 million and -$354.11 million in losses. Loss per share was -$1.62.
| Revenue | 46.24M |
| Gross Profit | 4.93M |
| Operating Income | -376.54M |
| Pretax Income | -358.95M |
| Net Income | -354.11M |
| EBITDA | -322.36M |
| EBIT | -358.95M |
| Loss Per Share | -$1.62 |
Balance Sheet
The company has $299.52 million in cash and $50.97 million in debt, giving a net cash position of $248.55 million or $1.05 per share.
| Cash & Cash Equivalents | 299.52M |
| Total Debt | 50.97M |
| Net Cash | 248.55M |
| Net Cash Per Share | $1.05 |
| Equity / Book Value | 401.15M |
| Book Value Per Share | 1.69 |
| Working Capital | 269.70M |
Cash Flow
In the last 12 months, operating cash flow was -$316.76 million and capital expenditures -$13.43 million, giving a free cash flow of -$330.20 million.
| Operating Cash Flow | -316.76M |
| Capital Expenditures | -13.43M |
| Free Cash Flow | -330.20M |
| FCF Per Share | -$1.40 |
Margins
Gross margin is 10.66%, with operating and profit margins of -814.39% and -765.90%.
| Gross Margin | 10.66% |
| Operating Margin | -814.39% |
| Pretax Margin | -776.37% |
| Profit Margin | -765.90% |
| EBITDA Margin | -697.21% |
| EBIT Margin | -776.37% |
| FCF Margin | -714.17% |
Dividends & Yields
RXRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.17% |
| Shareholder Yield | -23.17% |
| Earnings Yield | -15.73% |
| FCF Yield | -14.67% |
Analyst Forecast
The average price target for RXRX is $17.40, which is 84.71% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.40 |
| Price Target Difference | 84.71% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RXRX has an Altman Z-Score of 4.5 and a Piotroski F-Score of 4.
| Altman Z-Score | 4.5 |
| Piotroski F-Score | 4 |